View Item 

Show simple item record

Early tissue responses in psoriasis to the antitumour necrosis factor‐α biologic etanercept suggest reduced interleukin‐17 receptor expression and signalling
dc.contributor.authorJohnston, A.en_US
dc.contributor.authorGuzman, A.M.en_US
dc.contributor.authorSwindell, W.R.en_US
dc.contributor.authorWang, F.en_US
dc.contributor.authorKang, S.en_US
dc.contributor.authorGudjonsson, J.E.en_US
dc.date.accessioned2014-08-06T16:49:58Z
dc.date.availableWITHHELD_12_MONTHSen_US
dc.date.available2014-08-06T16:49:58Z
dc.date.issued2014-07en_US
dc.identifier.citationJohnston, A.; Guzman, A.M.; Swindell, W.R.; Wang, F.; Kang, S.; Gudjonsson, J.E. (2014). "Early tissue responses in psoriasis to the antitumour necrosis factor‐α biologic etanercept suggest reduced interleukin‐17 receptor expression and signalling." British Journal of Dermatology 171(1): 97-107.en_US
dc.identifier.issn0007-0963en_US
dc.identifier.issn1365-2133en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/108076
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherSpringeren_US
dc.titleEarly tissue responses in psoriasis to the antitumour necrosis factor‐α biologic etanercept suggest reduced interleukin‐17 receptor expression and signallingen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelDermatologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108076/1/bjd12937-sup-0005-TableS2.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108076/2/bjd12937-sup-0004-TableS1.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/108076/3/bjd12937.pdf
dc.identifier.doi10.1111/bjd.12937en_US
dc.identifier.sourceBritish Journal of Dermatologyen_US
dc.identifier.citedreferenceMenter A, Tyring SK, Gordon K et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008; 58: 106 – 15.en_US
dc.identifier.citedreferenceSmyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3:Article3.en_US
dc.identifier.citedreferenceStalteri MA, Harrison AP. Interpretation of multiple probe sets mapping to the same gene in Affymetrix GeneChips. BMC Bioinformatics 2007; 8: 13.en_US
dc.identifier.citedreferenceLottaz C, Yang X, Scheid S, Spang R. OrderedList – a bioconductor package for detecting similarity in ordered gene lists. Bioinformatics 2006; 22: 2315 – 16.en_US
dc.identifier.citedreferenceJohnston A, Xing X, Swindell WR et al. Susceptibility‐associated genetic variation at IL12B enhances Th1 polarization in psoriasis. Hum Mol Genet 2013; 22: 1807 – 15.en_US
dc.identifier.citedreferenceFalcon S, Gentleman R. Using GOstats to test gene lists for GO term association. Bioinformatics 2007; 23: 257 – 8.en_US
dc.identifier.citedreferenceElder JT, Fisher GJ, Zhang QY et al. Retinoic acid receptor gene expression in human skin. J Invest Dermatol 1991; 96: 425 – 33.en_US
dc.identifier.citedreferenceWang F, Smith N, Maier L et al. Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)‐19, IL‐20 and IL‐24. Br J Dermatol 2012; 167: 92 – 102.en_US
dc.identifier.citedreferenceBarker J, Hoffmann M, Wozel G et al. Efficacy and safety of infliximab vs. methotrexate in patients with moderate‐to‐severe plaque psoriasis: results of an open‐label, active‐controlled, randomized trial (RESTORE1). Br J Dermatol 2011; 165: 1109 – 17.en_US
dc.identifier.citedreferenceMrowietz U, Kragballe K, Reich K et al. An assessment of adalimumab efficacy in three phase III clinical trials using the European Consensus Programme criteria for psoriasis treatment goals. Br J Dermatol 2013; 168: 374 – 80.en_US
dc.identifier.citedreferenceLizzul PF, Aphale A, Malaviya R et al. Differential expression of phosphorylated NF‐κB/RelA in normal and psoriatic epidermis and downregulation of NF‐κB in response to treatment with etanercept. J Invest Dermatol 2005; 124: 1275 – 83.en_US
dc.identifier.citedreferenceGottlieb AB, Chamian F, Masud S et al. TNF inhibition rapidly down‐regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175: 2721 – 9.en_US
dc.identifier.citedreferenceZaba LC, Cardinale I, Gilleaudeau P et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204: 3183 – 94.en_US
dc.identifier.citedreferenceZaba LC, Suárez‐Fariñas M, Fuentes‐Duculan J et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL‐17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009; 124: 1022 – 30.e395.en_US
dc.identifier.citedreferenceHartupee J, Liu C, Novotny M et al. IL‐17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007; 179: 4135 – 41.en_US
dc.identifier.citedreferenceLeonardi C, Matheson R, Zachariae C et al. Anti‐interleukin‐17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190 – 9.en_US
dc.identifier.citedreferencePapp KA, Langley RG, Sigurgeirsson B et al. Efficacy and safety of secukinumab in the treatment of moderate‐to‐severe plaque psoriasis: a randomized, double‐blind, placebo‐controlled phase II dose‐ranging study. Br J Dermatol 2013; 168: 412 – 21.en_US
dc.identifier.citedreferencePapp KA, Leonardi C, Menter A et al. Brodalumab, an anti‐interleukin‐17‐receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181 – 9.en_US
dc.identifier.citedreferenceKrueger JG, Fretzin S, Suárez‐Fariñas M et al. IL‐17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol 2012; 130: 145 – 54.e9.en_US
dc.identifier.citedreferenceZaba LC, Fuentes‐Duculan J, Eungdamrong NJ et al. Identification of TNF‐related apoptosis‐inducing ligand and other molecules that distinguish inflammatory from resident dendritic cells in patients with psoriasis. J Allergy Clin Immunol 2010; 125: 1261 – 8.e9.en_US
dc.identifier.citedreferenceLeonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014 – 22.en_US
dc.identifier.citedreferenceMoreland LW, Schiff MH, Baumgartner SW et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med 1999; 130: 478 – 86.en_US
dc.identifier.citedreferenceTargan SR, Hanauer SB, van Deventer SJ et al. A short‐term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029 – 35.en_US
dc.identifier.citedreferenceMease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385 – 90.en_US
dc.identifier.citedreferenceFowler JF, Duh MS, Rovba L et al. The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 2008; 59: 772 – 80.en_US
dc.identifier.citedreferenceWilson NJ, Boniface K, Chan JR et al. Development, cytokine profile and function of human interleukin 17‐producing helper T cells. Nat Immunol 2007; 8: 950 – 7.en_US
dc.identifier.citedreferenceHijnen D, Knol EF, Gent YY et al. CD8 + T cells in the lesional skin of atopic dermatitis and psoriasis patients are an important source of IFN‐γ, IL‐13, IL‐17, and IL‐22. J Invest Dermatol 2013; 133: 973 – 9.en_US
dc.identifier.citedreferenceRes PC, Piskin G, de Boer OJ et al. Overrepresentation of IL‐17A and IL‐22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One 2010; 5: e14108.en_US
dc.identifier.citedreferenceEyerich S, Eyerich K, Pennino D et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119: 3573 – 85.en_US
dc.identifier.citedreferenceJohnston A, Fritz Y, Dawes SM et al. Keratinocyte overexpression of IL‐17C promotes psoriasiform skin inflammation. J Immunol 2013; 190: 2252 – 62.en_US
dc.identifier.citedreferenceGe D, You Z. Expression of interleukin‐17RC protein in normal human tissues. Int Arch Med 2008; 1: 19.en_US
dc.identifier.citedreferenceChiricozzi A, Guttman‐Yassky E, Suárez‐Fariñas M et al. Integrative responses to IL‐17 and TNF‐α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011; 131: 677 – 87.en_US
dc.identifier.citedreferenceKryczek I, Bruce AT, Gudjonsson JE et al. Induction of IL‐17 +  T cell trafficking and development by IFN‐γ: mechanism and pathological relevance in psoriasis. J Immunol 2008; 181: 4733 – 41.en_US
dc.identifier.citedreferenceJohnston A, Gudjonsson JE, Aphale A et al. EGFR and IL‐1 signaling synergistically promote keratinocyte antimicrobial defenses in a differentiation‐dependent manner. J Invest Dermatol 2011; 131: 329 – 37.en_US
dc.identifier.citedreferenceTeunissen MB, Koomen CW, de Waal Malefyt R et al. Interleukin‐17 and interferon‐gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111: 645 – 9.en_US
dc.identifier.citedreferenceGudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 2004; 135: 1 – 8.en_US
dc.identifier.citedreferenceNickoloff BJ, Xin H, Nestle FO, Qin JZ. The cytokine and chemokine network in psoriasis. Clin Dermatol 2007; 25: 568 – 73.en_US
dc.identifier.citedreferenceSwindell WR, Xing X, Stuart PE et al. Heterogeneity of inflammatory and cytokine networks in chronic plaque psoriasis. PLoS One 2012; 7: e34594.en_US
dc.identifier.citedreferenceBolstad BM, Collin F, Brettschneider J et al. Quality assessment of Affymetrix GeneChip Data. In: Bioinformatics and Computational Biology Solutions Using R and Bioconductor. ( R Gentleman, V Carey, W Huber, RA Irizarry, S Dudoit, eds), New York, NY: Springer, 2005, 33 – 47.en_US
dc.identifier.citedreferencePopova T, Mennerich D, Weith A, Quast K. Effect of RNA quality on transcript intensity levels in microarray analysis of human post‐mortem brain tissues. BMC Genomics 2008; 9: 91.en_US
dc.identifier.citedreferenceIrizarry RA, Bolstad BM, Collin F et al. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003; 31: e15.en_US
dc.identifier.citedreferenceLiu WM, Mei R, Di X et al. Analysis of high density expression microarrays with signed‐rank call algorithms. Bioinformatics 2002; 18: 1593 – 9.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
bjd12937-sup-0005-TableS2.pdf
Size:
17.75KB
Format:
PDF
View/Open
Name:
bjd12937-sup-0004-TableS1.pdf
Size:
18.50KB
Format:
PDF
View/Open
Name:
bjd12937.pdf
Size:
1.022MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.